Drug
Tesamorelin
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Product Dose Omission In Error | 51 | 25.2 | 26.0 | signal |
| 2 | Drug Effect Less Than Expected | 25 | 23.5 | 23.8 | signal |
| 3 | Product Administration Error | 31 | 20.6 | 21.0 | signal |
| 4 | Injection Site Nodule | 16 | 19.3 | 19.5 | signal |
| 5 | Intentional Dose Omission | 39 | 18.9 | 19.3 | signal |
| 6 | Therapeutic Product Effect Incomplete | 86 | 16.1 | 17.0 | signal |
| 7 | Injection Site Mass | 43 | 15.4 | 15.8 | signal |
| 8 | Injection Site Pruritus | 77 | 15.3 | 16.0 | signal |
| 9 | Carpal Tunnel Syndrome | 16 | 15.1 | 15.2 | signal |
| 10 | Injection Site Bruising | 89 | 14.9 | 15.8 | signal |
| 11 | Accidental Underdose | 16 | 14.5 | 14.7 | signal |
| 12 | Injection Site Discomfort | 11 | 14.1 | 14.2 | signal |
| 13 | Product Dose Omission Issue | 285 | 13.2 | 15.9 | signal |
| 14 | Product Preparation Error | 19 | 12.1 | 12.3 | signal |
| 15 | Spinal Operation | 10 | 10.9 | 11.0 | signal |
| 16 | Injection Site Discolouration | 10 | 10.7 | 10.7 | signal |
| 17 | Incorrect Dose Administered | 164 | 9.6 | 10.6 | signal |
| 18 | Injection Site Induration | 9 | 9.2 | 9.2 | signal |
| 19 | Injection Site Urticaria | 16 | 8.7 | 8.8 | signal |
| 20 | Treatment Noncompliance | 33 | 8.0 | 8.2 | signal |
| 21 | Weight Fluctuation | 6 | 7.6 | 7.6 | signal |
| 22 | Muscle Tightness | 9 | 7.4 | 7.4 | signal |
| 23 | Injection Site Irritation | 6 | 6.3 | 6.3 | signal |
| 24 | Injection Site Pain | 141 | 6.1 | 6.6 | signal |
| 25 | Product Administered At Inappropriate Site | 8 | 5.8 | 5.9 | signal |
| 26 | Weight Increased | 97 | 5.8 | 6.1 | signal |
| 27 | Injection Site Rash | 13 | 5.7 | 5.7 | signal |
| 28 | Joint Stiffness | 11 | 5.5 | 5.6 | signal |
| 29 | Glycosylated Haemoglobin Increased | 10 | 5.2 | 5.3 | signal |
| 30 | Wrong Technique In Product Usage Process | 78 | 5.1 | 5.3 | signal |
| 31 | Injection Site Haemorrhage | 27 | 4.5 | 4.6 | signal |
| 32 | Abnormal Weight Gain | 4 | 4.2 | 4.2 | signal |
| 33 | Product Storage Error | 27 | 4.1 | 4.2 | signal |
| 34 | Knee Operation | 3 | 4.1 | 4.1 | signal |
| 35 | Product Availability Issue | 6 | 3.5 | 3.5 | signal |
| 36 | Injection Site Erythema | 29 | 3.1 | 3.1 | signal |
| 37 | Injection Site Reaction | 16 | 3.1 | 3.1 | signal |
| 38 | Injection Site Swelling | 10 | 1.7 | 1.7 | no signal |
| 39 | Product Complaint | 3 | 1.6 | 1.6 | no signal |
| 40 | Gynaecomastia | 3 | 1.3 | 1.3 | no signal |
| 41 | Prostate Cancer | 7 | 1.1 | 1.1 | no signal |
| 42 | Device Difficult To Use | 3 | 0.6 | 0.6 | no signal |